Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Over 130 attendees worldwide attended our two-day seminar on Legal Considerations in Commercializing Gene-Edited Plants where we took attendees through a real world hypothetical explaining the use of gene editing in plant breeding. We covered the science behind gene-editing technology as well as the related IP, licensing, regulatory and compliance issues.

Legal Considerations in Commercializing Gene-Edited Plants: IP Protection, Licensing, Regulatory, and Compliance Issues

Over 130 attendees worldwide attended our two-day seminar on Legal Considerations in Commercializing Gene-Edited Plants where we took attendees through a real world hypothetical explaining the use of gene editing in plant breeding. We covered the science behind gene-editing technology as well as the related IP, licensing, regulatory and compliance issues.Gene editing has the potential to revolutionize agriculture and food production. However, to be successful, innovators need to address the challenges of IP protection and licensing as well as regulatory hurdles in order to successfully commercialize a product. Day one of this two-part webinar took attendees through a real world hypothetical that explained the use of gene editing in agriculture and we discussed freedom-to-operate and licensing issues for edited plants. On day two, we took a deep dive into the IP protection for edited plants and commercialization requirements for edited plants and food products through a discussion of CRISPR licenses, FDA, USDA, and EPA regulatory approvals and other commercialization issues.Day 1: Tuesday, June 8, 12:00 – 1:00 p.m. PDT<ul><li>Michael Ward, global head of Morrison & Foerster’s Life Sciences Practice Group, head of our Patent Practice Group, co-chair of our Intellectual Property Practice Group and co-chair of our global AgTech + Food Industry practice</li><li>Stephen Dellaporta, founder of Verinomics, a genomics and computational biology company serving the agriculture sector</li><li>Otis Littlefield, Senior Of Counsel, Patent, San Francisco</li><li>Matthew Karlyn, Partner, Life Sciences Transactions + Licensing, Boston</li><li>Wolfgang Schoenig, Partner, Life Sciences Transactions + Licensing, Berlin</li></ul><div class='youtube-wrapper'><iframe src="https://www.youtube-nocookie.com/embed/clkBadFlqu0?rel=0" title="Legal Considerations in Commercializing Gene-Edited Plants: Day 1" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="1"></iframe></div>Day 2: Wednesday, June 9, 12:00 – 1:00 p.m. PDT<ul><li>Michael Ward, global head of Morrison & Foerster’s Life Sciences Practice Group, head of our Patent Practice Group, co-chair of our Intellectual Property Practice Group and co-chair of our global AgTech + Food Industry practice</li><li>William Tarantino, Partner, Environmental Litigation + Regulatory, San Francisco</li><li>Wolfgang Schoenig, Partner, Life Sciences Transactions + Licensing, Berlin</li><li>Bethany Hills, Partner, FDA Regulatory + Life Sciences Compliance, New York</li></ul><div class='youtube-wrapper'><iframe src="https://www.youtube-nocookie.com/embed/-gfYcSbE370?rel=0" title="Legal Considerations in Commercializing Gene Edited Plants: Day 2" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="1"></iframe></div>Supplemental materials can also be found on our life sciences <a href="https://lifesciences.mofo.com/" target="_blank">blog</a> and <a href="/capabilities/food-agriculture.html">Food + Ag capabilities</a>.<hr>

Berkeley Center for Law & Technology and Morrison & Foerster LLP

Legal Considerations in Commercializing Gene-Edited Plants: IP Protection, Licensing, Regulatory, and Compliance Issues

Legal Considerations in Commercializing Gene-Edited Plants: IP Protection, Licensing, Regulatory, and Compliance Issues

08 Jun 2021 7:00 PM - 09 Jun 2021 8:00 PM